StemCyte
Blood & Organ Banks · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
13800 Live Oak Ave, Baldwin Park, Califo...Phone Number
(626) 646-2500Website
www.stemcyte.comRevenue
$18.1 MillionIndustry
About StemCyte
StemCyte, Inc. is a global leader in cord blood banking and regenerative therapeutics, established in 1997 and based in Baldwin Park, California. The company operates one of the few private and public cord blood banks worldwide, having facilitated over 2,300 transplants across more than 325 centers globally. StemCyte is recognized for its FDA-licensed cord blood-derived therapy, REGENECYTE, and holds both FACT and AABB accreditations. Their services are aimed at expectant families looking to preserve their newborn's cord blood for potential future medical treatments.Explore more
StemCyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to StemCyte
Compare insights from companies similar to StemCyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
StemCyte Tech Stack
A closer look at the technologies used by StemCyte
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding StemCyte
Sign Up For FreeTo access detailed company insights
StemCyte, Inc. is a global leader in cord blood banking and regenerative therapeutics, established in 1997 and based in Baldwin Park, California. The company operates one of the few private and public cord blood banks worldwide, having facilitated over 2,300 transplants across more than 325 centers globally. StemCyte is recognized for its FDA-licen... Read More
